qlm3003
Small moleculeexperimental
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
1
Earliest trial started Jun 25, 2023 (NCT05932888)
Timeline
Indications
Approved for
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06880276 | Phase 3 | Mar 31, 2025 | China Medical University, Qilu Pharmaceutical Co., Ltd., Shandong first medical University |
| NCT06058000 | Phase 2 | Oct 31, 2023 | China Medical University, Qilu Pharmaceutical Co., Ltd., Shandong first medical University |
| NCT06041529 | Phase 4 | Sep 14, 2023 | Catholic University of Korea, Yuhan Pharmaceutical Company |
| NCT05932888 | Phase 1 | Jun 25, 2023 | Central South University, Qilu Pharmaceutical Co., Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Qilu Pharmaceutical Co., Ltd. | For profit | 3 | 3 | 3 | 2023 |
| China Medical University | Academic/Hospital | 2 | 0 | 2 | 2023 |
| Shandong first medical University | Academic/Hospital | 2 | 0 | 2 | 2023 |
| Catholic University of Korea | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Central South University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Yuhan Pharmaceutical Company | For profit | 1 | 1 | 1 | 2023 |
6 organizations
Page 1 / 1